
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 23, 2023, titled "Glenmark Pharmaceuticals receives ANDA approval for Calcipotriene and Betamethasone Dipropionate Foam, 0.005% 0.064%".
Filed with NSE ·

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 23, 2023, titled "Glenmark Pharmaceuticals receives ANDA approval for Calcipotriene and Betamethasone Dipropionate Foam, 0.005% 0.064%".
6ix hasn’t read this filing yet.
Glenmark Pharmaceuticals Limited on 6ix
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals